Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
|
02 June 2017 |
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
|
22 May 2017 |
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
|
17 May 2017 |
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
|
04 May 2017 |
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
|
24 April 2017 |
Novartis expands development programs for NASH through clinical collaboration with Allergan
|
18 April 2017 |
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
|
07 April 2017 |
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
|
22 March 2017 |
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
|
20 March 2017 |
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
|
13 March 2017 |